Insulin-like growth factor-I and prostate cancer: a meta-analysis

Shi, Runhua; Berkel, Hans J.; Yu, Herbert

doi:10.1054/bjoc.2001.1961

Cited by 124 publications

(68 citation statements)

References 23 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[4][5][6] A recent breast cancer study found 5 SNPs to be associated with elevated plasma levels of IGF1, 10 and 4 of those SNPs were positioned in the region of Block 3, as defined in our study. Interestingly one of those 4 SNPs was rs6220, whose minor allele is the final C allele in the TCC and CCC risk haplotypes (Table III).…”

Section: Discussionsupporting

confidence: 62%

Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer

Johansson¹,

McKay²,

Stattin³

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Insulin-like growth factor-I (IGF1) stimulates cell proliferation, decreases apoptosis, and has been implicated in cancer development. Epidemiological studies have shown elevated levels of circulating IGF1 to be associated with increased risk of prostate cancer. To what extent genetic variation in the IGF1 gene is related to prostate cancer risk is largely unknown. We performed a comprehensive haplotype tagging (HT) assessment of single nucleotide polymorphisms (SNPs) representing the common haplotype variation in the IGF1 gene. We genotyped 10 SNPs (9 haplotype tagging SNPs (htSNPs)) within Cancer Prostate in Sweden (CAPS), a case-control study of 2,863 cases and 1,737 controls, in order to investigate if genetic variation in the IGF1 gene is associated with prostate cancer risk. Three haplotype blocks were identified across the IGF1 gene and 9 SNPs were selected as haplotype tagging SNPs. Common haplotypes in the block covering the 3 0 region of the IGF1 gene showed significant global association with prostate cancer risk (p = 0.004), with one particular haplotype giving an odds ratio of 1.46 (95% CI 5 1.15-1.84, p = 0.002). This haplotype had a prevalence of 5% in the study population. Our results indicate that common variation in the IGF1 gene, particularly in the 3 0 region, may affect prostate cancer risk. Further studies on genetic variations in the IGF1 gene in relation to prostate cancer risk as well as to circulating levels of IGF1 are needed to confirm this novel finding. ' 2006 Wiley-Liss, Inc.

show abstract

Section: Discussionsupporting

confidence: 62%

Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer

Johansson¹,

McKay²,

Stattin³

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Additionally, expression of the protumor insulin-like growth factor (IGF)-1 is upregulated while expression of the anti-tumor IGF-1 binding protein (IGFBP)-3 is suppressed. [28][29][30] As pancreatic b-islet cell loss accelerates, insulin production declines, potentially yielding a protective effect later on. Thus, an alternative explanation for our null findings is that the REDUCE cohort is balanced with respect to diabetes progression and our results merely reflect cancelation of opposing risks.…”

Section: Discussionmentioning

confidence: 99%

Diabetes and prostate cancer risk in the REDUCE trial

Moreira

Gerber

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to examine the link between diabetes and PCa risk in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, which required all subjects to undergo biopsy regardless of PSA. We further tested for interaction between diabetes and obesity. Diabetes status and body mass index (BMI) measurements were obtained at baseline. On multivariate analysis, diabetes was not associated with PCa risk (odds ratio (OR) 1.01, 95% confidence interval 0.79-1.30, P ¼ 0.92) or risk of low-or high-grade disease (all PX0.65). When stratified by obesity, diabetes was also not associated with PCa risk in any BMI category (all PX0.15). However, there was suggestion of effect modification by obesity for high-grade disease (P-interaction ¼ 0.053). Specifically, diabetes was associated with decreased risk of high-grade PCa in normal-weight men but increased risk in obese men (OR 0.35 vs 1.38). In the REDUCE trial, when all men underwent biopsy, diabetes was not associated with lower PCa risk, but rather equal risk of PCa, low-grade PCa and high-grade PCa.

show abstract

“…Several epidemiologic studies have reported a positive association between circulating insulin-like growth factor-I concentration and prostate cancer risk (53)(54)(55)(56)(57). Furthermore, in a recent meta-analysis of studies examining the association of circulating insulin-like growth factor-I concentrations with prostate cancer risk, Shi et al found that insulin-like growth factor-I blood levels were higher in prostate cancer patients than in controls (58). Thus, during the early stage of abnormal glucose metabolism and development of type 2 diabetes mellitus (the insulinresistant step), prostate cancer risk may be increased due to increasing levels of insulin.…”

Section: Discussionmentioning

confidence: 99%

Glycemic Status and Risk of Prostate Cancer

Darbinian

Ferrara

Eeden

et al. 2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: To examine the risk of prostate cancer and glucose tolerance in a large, racially diverse cohort. Methods: We conducted a cohort study of 47,209 male members of Kaiser Permanente Northern California who had completed at least one Multiphasic Health Checkup (MHC) between 1964 and 1973. The MHC provided information on diabetes, serum glucose 1 h after a 75-g oral glucose challenge test, demographics, and other health conditions. Cox proportional hazards were used to estimate relative risks (RR) while adjusting for confounders. Results: During a median follow-up of 18.4 years, a total of 2,833 men developed prostate cancer. At baseline, 4.6% (n = 2,159) of the cohort had diabetes and 33% had serum glucose of z200 mg/dL. After adjusting for age, race, birth year, and body mass index, RR (95% confidence interval) of prostate cancer

show abstract

Insulin-like growth factor-I and prostate cancer: a meta-analysis

Cited by 124 publications

References 23 publications

Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer

Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer

Diabetes and prostate cancer risk in the REDUCE trial

Glycemic Status and Risk of Prostate Cancer

Contact Info

Product

Resources

About